194 related articles for article (PubMed ID: 29329006)
1. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.
Başaran GA; Twelves C; Diéras V; Cortés J; Awada A
Cancer Treat Rev; 2018 Feb; 63():144-155. PubMed ID: 29329006
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.
Luo QQ; Adhikari VP; Zhao CX; Wu H; Dai W; Li X; Wu YT; Wu KN; Kong LQ
Med Hypotheses; 2016 Dec; 97():59-63. PubMed ID: 27876131
[TBL] [Abstract][Full Text] [Related]
5. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Lin PL; Hao Y; Xie J; Li N; Zhong Y; Zhou Z; Signorovitch JE; Wu EQ
Cancer Med; 2016 Feb; 5(2):209-20. PubMed ID: 26686532
[TBL] [Abstract][Full Text] [Related]
6. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
7. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
9. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
12. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
Gupta S; Zhang J; Jerusalem G
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198
[TBL] [Abstract][Full Text] [Related]
13. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
Watanabe J; Hayashi T; Tadokoro Y; Nishimura S; Takahashi K
Breast Cancer Res Treat; 2017 Dec; 166(3):911-917. PubMed ID: 28852946
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert T; de Paula B; Shafaee MN; Souza PH; Ellis MJ; Bines J
Chin Clin Oncol; 2018 Jun; 7(3):25. PubMed ID: 30056727
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Perez EA
Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Hart CD; Migliaccio I; Malorni L; Guarducci C; Biganzoli L; Di Leo A
Nat Rev Clin Oncol; 2015 Sep; 12(9):541-52. PubMed ID: 26011489
[TBL] [Abstract][Full Text] [Related]
18. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Glück S; Arteaga CL; Osborne CK
Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer.
Guérin A; Goldschmidt D; Small T; Gagnon-Sanschagrin P; Romdhani H; Gauthier G; Kelkar S; Wu EQ; Niravath P; Dalal AA
Adv Ther; 2018 Aug; 35(8):1251-1264. PubMed ID: 29946797
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]